Skip to main content

Table 3 Prevalence of all mutation

From: The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients

Mutation

% in whole series (%)

Overall mutational rate

60.2

NPM1

38.7

FLT3-ITD

24.5

c-KIT

48.4

N-RAS

25.8

IDH1

9.6

FLT3-TDK

5.1

IDH2

19.3

DNMT3A

9.6

WT1

12.9

RUNX1

9.6

TET2

0

ASXL1

0

WT1 high (expression)

84.6

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us